NCT05574881 2024-02-26
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
Fudan University
Phase 1/2 Unknown
Clinical Trials
31 trialsNCT05806047 2023-04-10
Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy
Fudan University
Phase 2 Unknown
NCT05806671 2023-04-10
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03772353 2023-03-07
PLEASURABLE
Fudan University
Phase 1/2 Unknown
NCT05411380 2022-11-04
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
Sun Yat-sen University
Phase 2 Unknown
NCT05577923 2022-10-13
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
Fudan University
Phase 2 Unknown
NCT05186545 2022-09-02
An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04334330 2022-05-02
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
Sun Yat-sen University
Phase 2 Unknown
NCT02909361 2022-04-20
Fulvestrant 500mg in Patients With Advanced Breast Cancer
Fudan University
Unknown
NCT02626507 2022-02-09
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
Hoffman Oncology
Phase 1 Unknown
NCT03633331 2021-10-15
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Unknown
NCT05076695 2021-10-13
NeoTPPF
Fudan University
Phase 2 Unknown
NCT05047848 2021-09-17
Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer
Liaoning Cancer Hospital & Institute
Phase NA Unknown
NCT04999540 2021-08-11
Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer
Guangdong Women and Children Hospital
Phase 2 Unknown
NCT04936295 2021-06-23
Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation
Sun Yat-sen University
Phase 2 Unknown
NCT04852081 2021-04-21
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
Blokhin's Russian Cancer Research Center
Unknown
NCT04753177 2021-02-15
The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
Phase 2/3 Unknown
NCT04034589 2020-12-22
Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT02690480 2020-02-05
FLIPPER
Spanish Breast Cancer Research Group
Phase 2 Unknown
NCT03925233 2019-04-24
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
Unknown
NCT03182634 2019-01-22
plasmaMATCH
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT03591549 2018-07-23
Fulvestrant in Metastatic Breast Cancer
Assiut University
Phase 4 Unknown
NCT02000193 2018-07-10
FANCY
Sun Yat-sen University
Phase 2 Unknown
NCT03560856 2018-06-18
PALPETBIO
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT03202862 2017-06-29
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
Fudan University
Phase 2 Unknown
NCT01266213 2017-05-01
FLAG
Samsung Medical Center
Phase 2 Unknown
NCT02383030 2016-06-15
FUMANCE
Consorzio Oncotech
Phase 3 Unknown
NCT02394496 2016-06-15
OVER
Consorzio Oncotech
Phase 3 Unknown
NCT02404051 2016-06-15
FEVEX
Consorzio Oncotech
Phase 3 Unknown
NCT02072512 2014-02-26
PROOF
Hospital Affiliated to Military Medical Science, Beijing
Phase 2 Unknown
NCT00927511 2011-07-22
FIDeS
Regina Elena Cancer Institute
Phase 2 Unknown